Study guide

5.3 Safe Administration, Handling & Infusion Toxicities

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

5.3 Safe Administration, Handling & Infusion Toxicities

Key Takeaways Explain This Topic AI

USP <800> and NIOSH standards require personal protective equipment (PPE) including double chemotherapy-tested gloves (ASTM D6978), non-permeable gowns, and negative-pressure containment primary engineering controls (C-PEC) for handling hazardous antineoplastic drugs.

Chemotherapy agents are classified by tissue damage potential: vesicants cause necrosis and sloughing, irritants cause local phlebitis, and flare reactions cause transient painless erythematous streaks along the vein path.

Extravasation of DNA-binding vesicants (anthracyclines) mandates dry cold compresses to localize the drug and prompt administration of IV Dexrazoxane (Totect); non-DNA-binding vesicants (vinca alkaloids) mandate dry warm compresses and local hyaluronidase injections.

Infusion-related hypersensitivity reactions (HSR) require immediate cessation of the infusion, patient assessment, IV normal saline flush, and administration of emergency protocols (H1/H2 blockers, corticosteroids, and IM epinephrine for anaphylaxis).

Closed System Drug-Transfer Devices (CSTDs) must be utilized during antineoplastic compounding and administration to prevent environmental contamination and occupational exposure.

Last updated: August 2026

3.3 Safe Administration, Handling & Infusion Toxicities

Clinical Pearl: The management of chemotherapy extravasation depends strictly on whether the vesicant is a DNA-binding agent (e.g., anthracyclines) or a non-DNA-binding agent (e.g., vinca alkaloids). Applying heat to an anthracycline extravasation enhances tissue penetration and worsens necrosis, whereas applying cold to a vinca alkaloid extravasation worsens local tissue toxicity. Remember: Cold for Anthracyclines, Warm for Vincas!

Hazardous Drug Safe Handling & USP <800> Standards

Handling antineoplastic agents presents significant occupational exposure risks, including mutagenicity, teratogenicity, carcinogenicity, and reproductive toxicity. The National Institute for Occupational Safety and Health (NIOSH) and USP Chapter <800> establish mandatory containment and safety standards across all healthcare settings.

Personal Protective Equipment (PPE) Requirements

Healthcare personnel compounding or administering antineoplastics (NIOSH Group 1 Hazardous Drugs) must utilize specific PPE:

Gloves: Must be tested for chemotherapy handling under ASTM D6978 standards. Powder-free gloves are required. Double gloving is mandatory: the inner glove under the gown cuff and the outer glove over the gown cuff. Outer gloves must be changed every 30 minutes or immediately if contaminated or torn.

Gowns: Must be disposable, lint-free, non-permeable (polyethylene-coated or laminated), and close in the back (no front openings). Gowns must be changed every 2 to 3 hours or immediately following a spill.

Respiratory & Eye Protection: Surgical N95 or NIOSH-approved respirators are required during activities generating aerosols or during spill management. Face shields or full goggles are mandatory when splash risk exists; standard prescription eyeglasses do not provide adequate eye protection.

Engineering Controls & Administration Devices

Containment Primary Engineering Control (C-PEC): Compounding must occur in a Class II, Type B2 or C1 Biological Safety Cabinet (BSC) or Compounding Aseptic Containment Isolator (CACI) operating under negative pressure and externally vented to the outside air through HEPA filtration.

Closed System Drug-Transfer Devices (CSTDs): CSTDs mechanically prohibit the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. USP <800> mandates the use of CSTDs during antineoplastic administration when the dosage form allows.

Chemotherapy Extravasation Management

Extravasation is the inadvertent infiltration of a vesicant or irritant antineoplastic drug into the perivascular or subcutaneous tissue.

Tissue Damage Classification

Vesicants: Cause severe tissue destruction, blistering, tissue necrosis, and ulceration that may require surgical excision or skin grafting (e.g., Anthracyclines, Vinca alkaloids, Mitomycin-C, Cisplatin >20 mL).

Irritants: Cause local inflammatory changes, phlebitis, tightness, or burning along the vein path without causing tissue necrosis (e.g., Carboplatin, Etoposide, Fluorouracil, Gemcitabine).

Exfoliants: Cause superficial tissue shedding or peeling without underlying tissue necrosis (e.g., Docetaxel, Paclitaxel).

Flare Reactions: Localized, painless erythematous streaking along the vein path, often accompanied by urticaria, without swelling or extravasation (common with Doxorubicin). Resolves spontaneously without intervention. Suspected Extravasation

  • │
  • ├─► 1. STOP Infusion Immediately
  • ├─► 2. Disconnect IV Tubing (DO NOT Flush Line)
  • ├─► 3. Aspirate Residual Drug with Syringe (3-5 mL)
  • ├─► 4. Remove Peripheral Cannula / Elevate Extremity
  • │
  • ├─► Classify Vesicant Type
  • │ │
  • │ ├─► DNA-Binding (Anthracyclines) ──► Apply COLD Compress + IV Dexrazoxane
  • │ │
  • │ └─► Non-DNA-Binding (Vinca Alkaloids) ─► Apply WARM Compress + SubQ Hyaluronidase
  • Specific Extravasation Antidote & Thermal Management Protocol

Vesicant Class Representative Agents Thermal Application Pharmacologic Antidote & Administration

DNA-Binding Vesicants Doxorubicin, Epirubicin, Daunorubicin, Idarubicin Dry COLD Compress (15–20 min QID for 48 hrs) to cause vasoconstriction and localize drug Dexrazoxane (Totect): Systemic IV infusion given over 1–2 hours for 3 consecutive days. Must initiate within 6 hours of extravasation. Day 1: 1000 mg/m²; Day 2: 1000 mg/m²; Day 3: 500 mg/m². Alternatives: Topical DMSO (99%).

Non-DNA-Binding Vesicants Vincristine, Vinblastine, Vinorelbine (etoposide is an irritant with vesicant potential, managed with the same warm-compress and hyaluronidase approach) Dry WARM Compress (15–20 min QID for 48 hrs) to cause vasodilation and drug dispersion Hyaluronidase: Subcutaneous injections into extravasation site. Inject 150–300 units SC divided into 4–5 clockwise injections around the site using a 25-gauge needle.

Platinum Compounds Cisplatin (concentrated >0.5 mg/mL or volume >20 mL) Dry COLD Compress Sodium Thiosulfate: 1/6 Molar (1.67%) solution. Inject 2–3 mL SC through existing catheter or percutaneously around the extravasation site.

Infusion-Related Reactions (IRR) & Hypersensitivity

Infusion-related toxicities range from mild flushing to life-threatening anaphylaxis.

Pathophysiologic Mechanisms

Type I IgE-Mediated Anaphylaxis: True allergic sensitization requiring prior exposure. Mediated by IgE cross-linking on mast cells/basophils, releasing histamine and leukotrienes. Classically seen with Platinum agents (Carboplatin, Oxaliplatin) occurring after multiple cycles (typically cycle 6 to 8).

Non-IgE Cytokine Release / Complement Activation (CARPA): Pseudo-allergic reaction occurring during the first or second infusion without prior sensitization. Mediated by massive cytokine release or complement cascade activation. Classically seen with Taxanes (Paclitaxel due to Cremophor EL) and Monoclonal Antibodies (Rituximab).

Emergency Management of Acute Hypersensitivity (CTCAE v5.0 Grade 3–4) Acute Hypersensitivity / Anaphylaxis Onset

  • │
  • ├─► 1. IMMEDIATELY STOP Infusion
  • ├─► 2. Call for Emergency Assistance & Assess Airway, Breathing, Circulation (ABCs)
  • ├─► 3. Disconnect Infusion Tubing; Maintain IV Access with 0.9% Normal Saline
  • ├─► 4. Administer Supplemental Oxygen (100% via non-rebreather mask)
  • ├─► 5. Elevate Patient's Legs (if hypotensive)
  • │
  • ▼ Emergency Pharmacotherapy
  • ├─► Epinephrine (1:1000 / 1 mg/mL): 0.3 to 0.5 mg IM into anterolateral thigh (repeat Q5-15 min)
  • ├─► Diphenhydramine: 50 mg IV push
  • ├─► Famotidine: 20 mg IV push
  • ├─► Methylprednisolone: 1 to 2 mg/kg IV push
  • └─► IV Fluid Bolus: 1 to 2 Liters 0.9% Normal Saline for persistent hypotension

Loading diagram... Chemotherapy Extravasation Classification & Emergency Antidote Algorithm